This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Advaxis" – news · newspapers · books · scholar · JSTOR (March 2012) (Learn how and when to remove this message) This article contains wording that promotes the subject in a subjective manner without imparting real information. Please remove or replace such wording and instead of making proclamations about a subject's importance, use facts and attribution to demonstrate that importance. (March 2012) (Learn how and when to remove this message) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (March 2012) (Learn how and when to remove this message) (Learn how and when to remove this message)
Advaxis Inc.
Company typePublic
OTCQX: ADXS
IndustryBiotechnology
Healthcare
PredecessorGreat Expectations, Inc.
FoundedMarch 1, 2002; 22 years ago (2002-03-01), in the United States
Headquarters
Princeton, New Jersey
,
United States
Key people
  • Ken Berlin (CEO)
  • Dr. Robert Petit (CSO)
  • Molly Henderson (CFO) Dr. Andres Gutierrez (CMO)
ProductsImmunotherapies for cancer
Websitewww.advaxis.com

Advaxis Inc. is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm).[1]: 1  The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.[1]: 1 

The Lm-based platform on which the company's products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer.[1]: 1  Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.[1]: 1 

Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with centers such as the National Cancer Institute, Cancer Research -UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.

The Company also has a veterinary medicine program that is evaluating an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. Source: www.advaxis.com

Corporate history and governance

Beginnings

Advaxis was a Delaware corporation when it was acquired by a shell corporation (in the official SEC sense)[2] in November 2004.[1]: 1  The acquiring company was Great Expectations, which was incorporated in Colorado in June 1987.[1]: 1  The only operating company owned by Great Expectations was Advaxis and in 2004, a month after the acquisition, it changed its name to Advaxis, and 18 months after that it reincorporated as a Delaware corporation.[1]: 1  The official 'date of inception' for the company is 1 March 2002.[1]: 1 

Partnerships

In 2014, Advaxis entered a co-development and commercialization agreement with India's Biocon for the ADXS-HPV therapeutic in the Indian market, addressing HPV-associated cancers, including cervical cancer.[1]: 2 ,[3]

Advaxis Technology

Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein. The vectors infect the key elements of the immune system and the secreted antigen/adjuvant fusion protein redirects the powerful immune response all human beings inherit to Lm against the cancer, itself. The adjuvant also reduces the cancer's defense against this immune attack by 80%.[4]

Clinical Development Program

ADXS-HPV is in Phase 2 trials for HPV-associated diseases (cervical intraepithelial neoplasia (CIN), cervical cancer and HPV-associated head and neck cancer).

In 2009 Advaxis published the results of the first Phase 1 trial with the first Lm-LLO based immunotherapy, ADXS-HPV in Vaccine (19 June 2009 / Volume 27, Issue 30). This study assessed side effects associated with increasing doses of ADXS-HPV in patients with metastatic, refractory, recurrent cervical cancer. Vaccine (19 June 2009 / Volume 27, Issue 30)

Veterinary Medicine Program

References

  1. ^ a b c d e f g h i "ADVAXIS, INC.", Investor Relations, Form 10-K, Advaxis, 2013, COMMISSION FILE NUMBER 000-28489, archived from the original on 2016-01-15, retrieved 16 March 2014
  2. ^ "Rule 12b-2 -- Definitions". Securities Lawyer's Deskbook. University of Cincinnati College of Law. Shell Company. Archived from the original on 16 March 2014. Retrieved 16 March 2014.
  3. ^ "Biocon, Advaxis Ink Deal for HPV-Associated Cancer Compound". News:Discovery & Development. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. 15 February 2014. p. 14.
  4. ^ "Advaxis Expects No Delay in Filing IND for ADXS-PSA" (Press release). Advaxis. 11 August 2011. Archived from the original on 3 September 2011. Retrieved 21 August 2011.
  5. ^ "Advaxis and Department of Homeland Security in Cooperative Research and Development Agreement". 2010-06-30.[permanent dead link]
  6. ^ "Advaxis and Department of Homeland Security Agree to Cooperative Research and Development Agreement" (PDF) (Press release). Advaxis. 2 June 2010. Archived from the original on 17 March 2014.
  7. ^ "Advaxis and U of P School of Veterinary Medicine Sign Contract". StreetInsider. 19 December 2008. Archived from the original on 4 March 2012.
  8. ^ "Advaxis Signs Veterinary Study Contract with the University of Pennsylvania School of Veterinary Medicine" (PDF) (Press release). Advaxis. 17 August 2010. Archived (PDF) from the original on 17 March 2014.
Categories